To date, neutralizing autoantibodies against the Th17 cytokines IL-17A, IL-17F, and IL-22 are suggested to explain the impairment in mucosal immunity in APS-1 patients [10,38]. Here, IL17F is linked to autoimmune polyendocrine syndrome type 1.